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for each step of the analysis cycle. At the end of each step
the external clock is reset as is the 8 bit control pattern for
the next function. The final step is to activate the AA
analysis cycle and to wait for the furnace to cool before in-
jection of the next sample. We have found that programming
a waiting time longer than the cooling time extends the life
of the graphite cuvettes. The program for operation in the
pulsed mode is given in Table 1.
The second injection is a critical part of the analysis cycle
for non-metals such as selenium and arsenic. The addition of
a co-analyte such as Ni2+ has been shown to increase the
sensitivity for these elements and reduces loss due to the
volatility of these elements 1, 5]. The syringe pump used
for the second injection delivers 11.0 + 0.1 /.tl/sec of co-
analyte. The same syringe pump is used for the total con-
sumption analysis mode. In the total consumption mode,
however, the analyte is pumped out of the holding tube into
the sampling valve and the dispensing of the sample then
proceeds in the same fashion as in the pulsed mode of
operation. The software modification for total consumption
analysis involves only increasing the second injection time to
4-8 seconds and performing the second injection prior to
the sample injection.
The graphite cuvette volume in the currently employed
AA system is approximately 50 /al and the standard pulsed
mode experiment employs 37/al + 1.7 ktl analyte from the
sampling loop and 1.0/al + 0.1 /al of co-analyte from the
syringe pump. The total consumption mode pumps 100
of eluent into the sampling loop and 37/.tl are then dispensed
into the graphite furnace. This ’overrun’ ensures the
complete filling of the sample loop and causes no problem in
subsequent interpretation of data.
Conclusion
The use of an inexpensive microprocessor system adds a
great deal of versatility to a previously "hard wired" LCAA
sampling system [1]. Both pulsed and total consumption
analyses are possible with only minor plumbing and software
changes. The use of other microprocessor systems would
require only a change in machine language. The system has
the advantage of being inexpensive. The interface sampling
system can be assembled for a component cost of approx-
imately $500 (depending on the availability of surplus
equipment).
With the many advantages of performing LCAA analysis
on trace level metal-containing compounds, hopefully this
technique will find widespread use with investigators in the
clinical, environmental, and inorganic biochemistry fields.
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Assessment of ENI Gemeni micro-
processor-controlled centrifugal
analyser
N. Potezny, R.G. White, and T.D. Geary
Institute ofMedical and Veterinary Science, Box 14, Rundle Street PO, Adelaide, South Australia, 5000.
The ENI Gemeni was assessed in this institute for its suita-
bility as a general laboratory instrument using a procedure
which has been developed during the last two years for the
Committee for Evaluation of Kits and Instrumentation of
the Australian Association of Clinical Biochemists.
Materials and Methods
The Gemeni is a miniature centrifugal analyser consisting of
an analyser module, microprocessor and work station.
The methods recommended by the manufacturer for use
on the Gemeni were run in parallel with routine methods
used in this laboratory. These routine methods were:
(1) Glucose Glucose Analyser, Yellow Springs Inst.
Co. (YSI).
(2) Cholesterol Abbott Agent Enzymatic Reagent,
Abbott ABA 100.
(3) Calcium Cresolphthalein complexone, SMAC,
Technicon Equipment Pty. Ltd.
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(4) Alkaline
(5) Phosphatase p-nitrophenol, Beckman TR.
These methods have known accuracies and precisions.
The Center of Disease Control, Atlanta, USA, (CDC)
hexokinase reference method was used to check the YSI
glucose analyser. The cholesterol method has been standard-
ised against the WHO Lipid Standardisation Laboratory at
CDC. The calcium method has been compared with the
Call, Young and Bowers [1] method using materials from
the Massachusetts Society of Pathology with definitive
values assigned by an isotope dilution technique.
The method of assessment was based upon the work of
Tonks [2], Barnett and Youden [3], Logan [4], Broughton
et al [5] and modified in the light of our own experience.
Precision
(a) Intrabatch imprecision was checked by the analyses of
replicates in the same batch and duplicates on the patient
comparisons.
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Figure 1. Glucose
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Figure 2. Cholesterol
(b) Interbatch imprecision was assessed by analysing control
materials at three levels, twice a day for a period of ten
days. The materials were selected to coincide with
decision levels, and to cover the linear range of the
analyte to be determined.
Recovery
Constituents were added to pooled sera so that the final
concentrations represented typical ranges of normal and
abnormal values encountered in patient sera.
Accuracy
Bias was checked by comparing patient samples against a
reference method or one of known bias. These were used in
Table 1
Intrabatch Imprecision
Mean
SD
CV%
Glucose Cholesterol
mmol/1 mmol/1
9.36 4.42
0.11 0.06
1.18 1,.43
Calcium
mmol/1
2.47
0.05
1.90
Alkaline Phosphatase
U/1
102.9
2.63
2.56
Table 2
Interbatch Imprecision
Glucose mmol/1
Low
Medium
High
Cholesterol mmol/1
Low
Medium
High
Calcium mmol/1
Low
Medium
High
Alkaline Phosphatase U/1
Low
Medium
High
Mean SD 2 CV% ALE
2.16 0.12 11.12 10.0
6.11 0.24 7.86 10.0
18.67 0.39 4.18 10.0
2.28 0.06 5.26 10.0
6.10 0.19 6.22 10.0
12.75 0.39 6.12 10.0
1.73 0.07 8.10 6.0
2.66 0.08 6.10 6.0
3.70 0.08 4.32 6.0
29.3 1.87 12.76 20.0
73.3 4.08 11.14 20.0
261.2 9.02 6.90 20.0
conjunction with quality control material with consensus
values from the Comprehensive Chemistry Quality Assurance
Programme, College of American Pathologists, or materials
with assigned values from CDC. As a further guide to accuracy
a number of commercial control materials were assayed. The
results tabulated for quality control material are the means
of triplicate analysis.
Linearity
Linearity was checked for the four parameters assayed. For
glucose, cholesterol and calcium this was achieved by assaying
aqueous standards, while for alkaline phosphatase a high
patient serum was diluted in pooled sera with low values.
Literature score
The literature score was obtained by the method of Krynski
and Logan [6] using the recommendations of the American
Association of Clinical Chemists Committee on Standards
[7].
Miscellaneous tests
The precision and accuracy of the reagent dispenser was
checked.
The precision and accuracy of delivering a pre-set volume
of reagent was determined at two volume settings. This was
achieved by dispensing set volumes of distilled water into
a weighing tray and weighing the amount of water dispensed.
Several days were allowed in which to become familiar
with the instrument prior to the commencement of the
evaluation. The familiarisation protocol consisted of the
following points:
(a) Instrument installed by the distributor.
(b) Instrument operated by laboratory staff under the
distributor’s supervision.
(c) A verification procedure undertaken in the presence of
.the distributor to check that the instrument was per-
forming to manufacturer’s specifications.
(d) Final acceptance by both the distributor and evaluators.
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Figure 4. Alkaline phosphatase.
Results
Precision
(a) Intrabatch imprecision for the analytes tested are given
in Table 1.
(b) Interbatch imprecision results are given in Table 2.
From the results in Table and 2, it can be seen that
alkaline phosphatase and cholesterol have acceptable degrees
of imprecision over the range of values assayed.
Imprecision for glucose was unacceptable by Top.k’s
criterion 2 CV% ALE (allowable limits of error) at the
low level. However, this level of imprecision at such a low
glucose concentration is clinically acceptable. The calcium
methodology had unacceptable imprecision at low and
medium levels.
Recovery
Table 3 shows the recovery data for glucose determination.
Recovery data were made for glucose only for two reasons.
The report is primarily an assessment of the instrument, and
not the kits, and the instrument had to be returned to the
distributor before a ’complete evaluation’ could be completed.
The recoveries were acceptable by Logan’s criteria, i.e.
acceptable recoveries average between 90% and 110% with
no single recovery less than 85% or greater than 115%.
Accuracy
(a) Patient comparison
The computer plot of the patient comparison data is
shown in Figures 1, 2, 3 and 4. Applying the "t" test, all
the Gemeni results except alkaline phosphatase are
significantly different from the comparative methods.
Results of the "t" test were as follows: glucose 3.30,
cholesterol 11.00, calcium 3.68 and alkaline phosphatase
1.5. This must be viewed in its proper context; a result
may be statistically significant but clinically acceptable.
If the "t" test is significant then further criteria are
applied, that is a kit is unacceptable if:
(1) The bias exceeds-the allowable limits of error for
precision.
(2) The number of false clinical decisions exceeds 5%.
Table 3
Glucose Recovery
Sample
Pooled serum
P+3.0
P+6.0
P+12.0
Mean Value mmol/1
6.6
9.4
12.4
18.5
Recovery %
93
97
99
Table 4
Glucose Accuracy
Control
CDC
CDC 2
CAP C1
CAP C2
CAP C3
Monitrol
Monitrol 11
QPAK
QPAK 11
Versatol A Alternate
Table 5
Cholesterol Accuracy
Control
Q Pak
Q Pak 11
Versatol A Alternate
Monitrol
Serachol
Lipidtrol
Calbiochem lipid
control A
Calbiochem lipid
control B
Value mmol/1
4.3
7.3
5.6
5.8
5.7
4.9
11.8
5.2
11.3
17.2
Observed value
4.3
7.3
5.5
5.8
5.6
4.6
12.0
5.3
11.3
17.1
Value mmol/1
2.9
2.9
2.85
4.12
10.1
8.1
11.3
3.1
Observed value
mmol/1
2.75
2.75
2.35
3.52
10.0
8.4
11.1
3.1
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Table 6
Alkaline Phosphatase Accuracy
Value U/1
109
343
419
40
220
195
Q’Pak
QPak 11
Q Pak multi-enzyme
control C
Monitrol
Monitrol 11
Validate
Observed value
U/1
98
340
347
54
210
215
Table 7
Calcium Accuracy
Control
CAP C1
CAP C2
CAP C3
Validate A
Validate
Monitrol
Monitrol 11
QPakl
QPak 11
Versatol A Alternate
Value mmol/1
2.45
2.58
2.45
3.43
2.35
2.45
2.18
2.38
3.35
3.20
Observed value
2-.40
2.50
2.45
3.38
2.30
2.43
2.25
2.38
3.18
3.08
Based on these criteria of acceptability, the results for
glucose, cholesterol and alkaline phosphatase are accept-
able, while those obtained for calcium.are unacceptable.
(b) Comparison of results on commercial control material
Bias less than allowable limits of error for precision from
a carefully verified reference serum value which relates
to all parameters tested, indicates that the test method
gives a satisfactory measurement of the "true value".
Results obtained for control sera are shown in Tables
4, 5, 6 and 7. These indicate that accuracy is acceptable
for glucose, cholesterol and alkaline phosphatase but
unacceptable for the calcium methodology.
Linearity
Linearity for the methods tested
glucose linear to 20 mmol/1
cholesterol linear to 15 mmol/1
alkaline phosphatase linear to 400 U/1
calcium linear to 3.75 mmol/1
was as follows:
Literature score
One mark was assigned for each point covered in the inform-
ation supplied by the manufacturer. One half mark was
awarded for each point that had received only partial
attention. In case of doubt the scoring favoured the manu-
facturer.
The Gemeni’s literature scored 13 out of a possible 15
points.
Miscellaneous tests
Precision and accuracy of Clay.Adams Selectapette.
Results obtained were as follows:
(a) Volume pre-set to deliver 1.0 ml
Mean volume delivered 1.000 ml
CV% 0.3
(b) Volume pre-set to deliver 0.5 ml
Mean volume delivered 0.500 ml
cv% 0.4
These results are. within the limits of acceptability for
accuracy and precision i.e:
IIII IIII II11 IIII
(a) accuracy 1% stated volume
(b) precision CV less than 1%
Discussion
Precision for cholesterol and alkaline phosphatase methodo-
logies was acceptable over the range of values assayed.
Glucose precision was acceptable at medium and high concen-
trations; at low concentrations precision was unacceptable
by Tonk’s criterion. However, at such low glucose concen-
tration the precision is clinically acceptable. The calcium
method proved unacceptable by Tonk’s criterion at low and
medium levels.
The accuracy for glucose, cholesterol and alkaline phos-
phatase were acceptable. The results obtained for the calcium
kit were unacceptable.
A feature of the instrument which will aid quality control
programmes is the print out of a ’quality control factor’ and
a reagent drift at the end of each run. A draw back with the
instrument is its lack of flexibility. The microprocessor
program is selected by coded holes in the test card. This
makes it impossible to alter parameters in the program and,
therefore, difficult to use kits produced by other manufac-
turers.
The instrument performed creditably throughout the
evaluation and proved to be easy to operate, giving precise
and accurate results for cholesterol glucose and alkaline
phosphatase. However the quality of results from the calcium
kits were unacceptable. When the results for the other
analytes are considered this would appear to be a fault of the
method rather than the instrument.
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